Navigation Links
Progress Reported in Predicting Alzheimer's
Date:1/19/2011

By Randy Dotinga
HealthDay Reporter

TUESDAY, Jan. 18 (HealthDay News) -- Researchers report promising results for a scanning test that aims to reveal the presence of Alzheimer's disease, potentially allowing doctors to try to treat the illness in its early stages. Another study finds that blood tests could indicate higher risks of dementia later in life.

But there's a catch: Alzheimer's disease is not curable, and existing treatments only have limited effects.

Even so, the ability to precisely diagnose Alzheimer's disease during life, which is now impossible, could lead to improved research, said memory specialist Dr. Anton P. Porsteinsson, a psychiatry professor at the University of Rochester School of Medicine, who was not involved with the studies.

The findings, published Jan. 19 in the Journal of the American Medical Association, "may have much more relevance" in the future, Porsteinsson said. "Basically, this is a step in the process."

Currently, doctors correctly diagnose Alzheimer's disease about 85 percent of the time, Porsteinsson said. The illness can be confirmed only through brain analysis after death. Even with existing scanning technology, "we can't see individual cells or what's going on," he said. "We can't see the functional impairment that happens," he added.

In one of the new studies, researchers led by a team from Avid Radiopharmaceuticals reported that they were able to find signs of Alzheimer's disease by using PET scanning technology. They had scanned 35 people who appeared to have the disease before their deaths and looked for signs of beta amyloid, a kind of gunk that clogs the brain in people with the illness.

The other study attempted to measure levels of beta amyloid in the blood. It linked lower levels -- a sign that the gunk is getting tied up in the brain -- to higher cognitive problems in 997 elderly people over a nine-year period.

The researchers also found that people with higher levels of "cognitive reserve" -- such as those with higher levels of education and literacy -- seemed to be buffered against dementia, said the study's lead author, Dr. Kristine Yaffe, a psychiatrist and professor at the University of California, San Francisco.

"The fascinating implication is that if you identify those at risk, maybe you could do something like cognitive stimulation to mitigate the risk," she said.

For now, though, "the markers reported here are far too unspecific to distinguish between people who will and will not get the disease," said Dr. Monique M.B. Breteler, an epidemiologist with University Medical Center Rotterdam in the Netherlands who wrote an accompanying commentary. "The importance of this paper is that it shows that there are detectable signals in blood that are related to the later development of the disease."

As for cost, Porsteinsson said the expense of the blood tests may go down. As to the other study, "the cost for the PET scans will always be pretty high because you've got to have such expensive tools."

More information

The U.S. National Institute on Aging has more on Alzheimer's disease.

SOURCES: Anton P. Porsteinsson, M.D., professor, psychiatry, University of Rochester School of Medicine, Rochester, N.Y.; Kristine Yaffe, M.D., endowed chair in psychiatry, University of California, San Francisco, and chief, geriatric psychiatry, San Francisco VA Medical Center; Monique M.B. Breteler, M.D., Ph.D., head, neuroepidemiology section, University Medical Center, Rotterdam, the Netherlands; Jan. 19, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Walking slows progression of Alzheimers
2. New STD Report Finds Some Progress, High Costs for U.S.
3. New indicator found for rapidly progressing form of deadly lung disease
4. Insufficient vitamin D levels in CLL patients linked to cancer progression and death
5. Stereotactic radiotherapy slows pancreatic cancer progression for inoperable patients
6. Surprise finding: Pancreatic cancers progress to lethal stage slowly
7. Neuralstem updates ALS clinical trial progress
8. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
9. Diabetes gene linked to degeneration of enzyme involved in Alzheimers disease onset and progression
10. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
11. Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Progress Reported in Predicting Alzheimer's
(Date:2/23/2017)... , ... February 23, 2017 , ... ... approved content provider for the National Institute for Health and Care Excellence ... care-related organizations in the National Health Service (NHS) to search, order and purchase ...
(Date:2/23/2017)... ... 2017 , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice ... a 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier ... physicians and dentists who have earned high ratings and superior patient reviews from multiple ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
(Date:2/23/2017)... ... 2017 , ... Healthcare Research & Analytics® (HRA®) in cooperation ... cancer, has produced a seminal study that asked cancer survivors and their caregivers ... a webinar, Defining Compassionate Care Through the Voices of Patients and Advocates that ...
(Date:2/23/2017)... Vienna, VA – , ... ... is coming. It’s the perfect opportunity for the nation to ... out a college basketball bracket – with its favorite fruit ... Association is encouraging apple lovers to join the “Apple Madness” ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australien, 24. Februar 2017 ... diversifiziertes Unternehmen des Gesundheitsbereiches, ist erfreut, für das ... mit dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu ... und Aktualisierung zum Wachstum" finden Sie hier ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; ...
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... 2016" report to their offering. ... The latest research Autism Spectrum Disorder Drugs ... benchmarks in the global Autism Spectrum Disorder market. The research ... the key drugs marketed for Autism Spectrum Disorder and their clinical ...
Breaking Medicine Technology: